Abstract Enteral probiotics such as Lactobacillus casei GG (LGG) have been used in the treatment of a variety of intestinal disorders in infants and children, including diarrhea, malabsorption, and Clostridium dicile colitis. We have previously demonstrated that the probiotic bacterium LGG has an inhibitory eect on bacterial translocation (BT) in a neonatal rabbit model. However, this in-vivo model is limited for investigating the cellular and molecular mechanisms responsible for probiotic inhibition of BT. The purpose of this study was to determine the ecacy of LGG in reducing the rate of Escherichia coli C25 (E. coli C25) translocation using an in-vitro enterocyte cell-culture model. Human colonic carcinoma (Caco-2) enterocytes were seeded in porous ®lters in the apical chamber of a two-chamber cellculture system and grown for 14 days to con¯uence. The monolayers were incubated at 37°C with LGG for 180 min. Non-adherent LGG was washed away prior to a 120-min incubation period with 10 5 CFU E. coli C25. E. coli that had translocated across the enterocyte monolayer were quanti®ed by growing basal-chamber media samples on gram-negative bacteria-speci®c MacConkey's agar. In order to determine monolayer integrity, transepithelial electrical resistance (TEER) was measured across Caco-2 cells treated with LGG and E. coli. Statistical analysis was by ANOVA with P < 0.05 considered signi®cant.
Introduction
More than 20 years ago, Fuller de®ned probiotics as:``A live microbial feed supplement, which bene®cially aects the host animal by improving its intestinal microbial balance'' [8, 9] . Recently, probiotic organisms have been advocated for stabilizing the gut micro¯ora in conditions where disturbances of the normal bacterial¯ora result in a wide range of gastrointestinal symptoms [2, 8, 9, 13] . Lactobacillus casei Rhamnosus (Lactobacillus GG, LGG) has been shown to be bene®cial in the treatment of antibiotic-induced diarrheal disease, diarrhea, malabsorption, Clostridium dicile colitis, inammatory bowel disease, Helicobacter pylori gastroenteritis, lactose intolerance, and irritable bowel syndrome [1, 2, 7, 8, 10, 14, 15, 20] . It has been reported that LGG adheres to cultured enterocytes and has an inhibitory eect on the pathogenesis of several bacteria like Salmonella typhimurium, diarrheogenic Escherichia coli, Campylobacter jejuni, and Clostridium dicile [1, 7, 11, 14, 15, 19, 20] . The ability to adhere to human colonic carcinoma (Caco-2) enterocytes in culture has provided one explanation for the ability of LGG to colonize the intestine [3±6]. However, the exact mechanism(s) by which LGG might inhibit pathogenic bacteria is unknown. We have previously demonstrated that LGG has an inhibitory eect on bacterial translocation (BT) in a neonatal rabbit model [16] . The aim of this study was to determine the ecacy of LGG in reducing the degree of E. coli C25 translocation using an in-vitro enterocyte cell-culture model and to study possible mechanisms of this inhibition.
Materials and methods
E. coli C25, a mild to moderately virulent, streptomycin-resistant strain originally isolated from a neonate with necrotizing enterocolitis, was kindly provided by Dr. Henri R. Ford (Pittsburgh, PA). The organisms were grown overnight in brain±heart infusion medium (BBL, Cockeysville, MD), washed two times with phosphate-buered saline (PBS), and resuspended in Dulbecco's modi®ed Eagle's medium (DMEM) (Fisher Scienti®c, Pittsburgh, PA) at a concentration of 10 5 colony-forming units (CFU)/ml. The initial concentration of the bacteria was determined by spectrophotometry at 650 nm and the numbers of bacteria were veri®ed by pour-plate assay using MacConkey's agar (Difco, Detroit, MI) and standard serial dilution techniques. LGG (ATCC 53103) obtained from the American Type Culture Collection (ATCC, Manassas, VA) was grown overnight in Ragosa SL broth (Difco), washed two times with PBS, and resuspended in DMEM at a concentration of 10 6 CFU/ml. The initial concentration of LGG was determined by spectrophotometry at 600 nm and the numbers were veri®ed by pour-plate assay as mentioned above.
Caco-2 cells were obtained from the American Type Culture Collection (No. HTB 37). Cell passages 25±37 were grown in DMEM supplemented with 10% fetal bovine serum, 1% nonessential amino-acid solution, 1% sodium pyruvate, penicillin G (100 IU/ml), and streptomycin (100 lg/ml) in a 5% CO 2 atmosphere at 37°C. After the cells were grown to 70% con¯uence, they were harvested following trypsinization with trypsin-EDTA (Gibco, Grand Island, NY), washed, and resuspended in DMEM. The cells were seeded at a density of 1´10 5 per well into collagencoated porous ®lters in the apical chamber of a two-chamber cellculture system. Collagen coating of the plates was accomplished by incubating in 30 ll 1.0 mg/ml rat-tail type I collagen (Sigma, St Louis). The cells were grown for 14 days to con¯uence and full dierentiation. Media were changed every other day. The formation of an intact, con¯uent monolayer of Caco-2 cells was monitored by measuring the transepithelial electrical resistance (TEER) with a Millicell electrical resistance system (Millipore EVOM-6: World Precision Instruments, Sarasota, FL). TEER re¯ects the integrity of the monolayer; as TEER increases, the tight junctions between the cells become stronger and the permeability of the monolayer decreases.
Caco-2 monolayers were washed three times with DMEM without fetal bovine serum or antibiotic supplements and``pre-TEER'' was measured. The Caco-2 cells were then incubated at 37°C for 180 min with 10 6 CFU LGG for 180 min, followed by the addition of 10 5 CFU E. coli C25 for 120 min. The inner chamber containing the monolayer was then transferred to a new outer chamber and new medium was added to both the apical and basal chambers; post-BT TEER was then measured.
To evaluate the inhibitory eects of dierent LGG doses, the Caco-2 monolayers were pre-incubated at 37°C with LGG at 0, 10 4 , 10 5
, and 10 8 CFU/ml for 180 min. To remove the non-adherent LGG, the enterocyte monolayers were washed three times with PBS (the washes were cultured to rule out the presence of any free LGG) prior to a 120-min incubation period with 10 5 CFU E. coli C25. The inner chamber containing the monolayer was then transferred to a new chamber and new medium was added to both apical and basal chambers, then post-BT TEER was measured.
During the experiment the cell-culture wells were maintained in a 5% CO 2 incubator at 37°C. The integrity of the Caco-2 monolayers was monitored by measuring the TEER of each 12-mm transwell. In order to calculate the resistance, the blank-well TEER was subtracted from the subsequent TEER measurements. The E. coli that had translocated across the enterocyte monolayer were quanti®ed by growing basal-chamber media samples on gramnegative bacteria-speci®c MacConkey's agar using standard serial dilution techniques. Colony counts were determined and statistical analysis between treatment groups was by ANOVA with P below 0.5 considered signi®cant.
Results

Eect of
LGG on E. coli BT E. coli C25 BT in the standard Caco-2 cell in-vitro system was signi®cantly inhibited across monolayers treated with LGG (2.2 0.04 log 10 CFU/ml) versus controls (4.01 0.13 log 10 CFU/ml, P < 0.05) (Fig. 1) . This experiment demonstrates that LGG can inhibit BT when both organisms are simultaneously applied to the apical side of the transwell Caco-2 cell monolayer system, mimicking the in-vivo scenario of the gut lumen.
Possible mechanism of LGG inhibition of BT
In order to determine whether LGG inhibition of BT in our in-vitro enterocyte model required direct LGG± E. coli interaction, LGG was washed away from the surface of the Caco-2 monolayer prior to the addition of E. coli. First, control experiments were conducted to determine the number of washes required to insure that LGG was adequately removed from the incubation media prior to adding E. coli. It was determined that three serial washes were required (Fig. 2) . Based on this experiment, to remove all unbound LGG from the apical chamber three washes were used in the subsequent experiments. A signi®cant inhibitory eect of LGG on E. coli translocation was observed after removal of unbound LGG (1.16 0.03 log 10 CFU/ml) versus controls (3.37 0.4 log 10 CFU/ml; P < 0.01) (Fig. 3) . The result of this experiment suggests that LGG acts on the enterocyte in order to inhibit BT. Dose-dependent eect of LGG inhibition of BT E. coli translocation was inhibited by LGG in a dosedependent manner as follows: 21.7% for 10 4 LGG, 28.8% for 10 5 LGG, 36.6% for 10 6 LGG, and 50.2% for LGG and E. coli or E. coli alone. *P < 0.05 10 7 LGG concentrations. The highest concentration of LGG tested (10 8 ) resulted in complete inhibition (100%) of E. coli (Fig. 4) .
Eect of LGG on transepithelial electrical resistance
The TEER ratio was measured before three serial washings (pre-TEER to remove unbound LGG and after addition and incubation of E. coli (post-TEER). TEER allows the assessment of monolayer integrity and tight-junction function. The mean TEER ratio (post-TEER/pre-TEER) across Caco-2 monolayers treated with E. coli alone (control) was 0.9 0.03 versus 0.8 0.05 for LGG (plus E. coli)-treated monolayers. These data indicate that serial washings as well as the addition of LGG had no signi®cant eect on nonspeci®c monolayer permeability or integrity (Fig. 5) .
Discussion
Probiotics are de®ned as live organisms that, when ingested, result in health bene®ts including amelioration or prevention of a speci®c disease state. LGG has been used in vivo to treat a variety of conditions, including antibiotic-induced diarrhea, diarrhea, malabsorption, C. dicile colitis, in¯ammatory bowel disease, H. pylori gastroenteritis, lactose intolerance, and irritable bowel syndrome [10, 16, 18±20] .
A number of mechanisms have been described that promote the health bene®ts of probiotics. For example, these organisms are known to enhance the intestinal micro¯ora by replenishing suppressed bacteria and inhibiting the growth of pathogenic¯ora [8, 21, 22] . In addition, some probiotics, including LGG, actively secrete anti-microbial substances that have been shown to inhibit the growth of other organisms such as S. typhimurium, diarrheogenic E. coli, C. jejuni, and C. dicile [1, 7, 14, 15, 19, 20] .
In this study, we describe an in-vitro enterocyte cellculture model that has allowed investigation of the effects of LGG on E. coli translocation. We found that the addition of LGG to the enterocyte monolayer surface result in signi®cant inhibition of BT. These results suggest that the inhibitory eect of LGG on BT is not a consequence of a generalized increase in tight-junction LGG and E. coli or E. coli alone after washing unbound LGG from apical chamber. *P < 0.01 permeability. However, our results do provide insight into possible mechanisms by which LGG might inhibit E. coli translocation. The inhibitor eect of LGG was not abolished by removing pre-incubated LGG prior to testing for BT. This indicates that there is a direct eect of LGG on enterocytes that persists after removal of LGG and results in diminished passage of E. coli across the epithelial monolayer.
LGG could bind to enterocyte cell-surface receptors (and not be removed by washing), thus competing with E. coli enterocyte attachment. Another possible mechanism is that LGG signals the enterocyte through direct binding or secreted substances to up-regulate epithelial barrier mechanisms. In our study, LGG did not signi®-cantly increase TEER, arguing against this as a possible mechanism of BT inhibition. Mack et al. have recently reported that LGG can inhibit BT in an HT-29 intestinal epithelial cell-culture model by up-regulating expression of several mucin molecules that are components of the epithelial barrier [12, 17] . It is possible that a similar mechanism is involved in the inhibition of E. coli translocation by LGG demonstrated in our current study.
In conclusion, we have shown that the probiotic LGG inhibits the translocation of E. coli C25 across an enterocyte monolayer in vitro. This eect appears to be secondary to an interaction between probiotic and enterocyte. This model should prove helpful in further de®ning mechanisms by which probiotics such as LGG inhibit translocation of potentially pathogenic enteral micoorganisms that could contribute to sepsis.
